Skip to search formSkip to main contentSkip to account menu

Filgrastim

Known as: R metHuG CSF, R-metHuG-CSF, Filgrastim XM02 
A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating… 
National Institutes of Health

Related topics

Related topics

29 relations
0.8 ML FILGRASTIM-SNDZ 0.6 MG/ML Prefilled Syringe0.8 ML Filgrastim 0.6 MG/ML Prefilled Syringe [Neupogen]1 ML Filgrastim 0.3 MG/ML Injection [Neupogen]CSF3 gene

Broader (3)

Colony-Stimulating FactorsHematologic AgentsRecombinant Proteins

Narrower (3)

NeupogenTopneuterZarxio

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality.
6598 Background: In a multicenter placebo-controlled study, LEN (10 mg/day for 1–21 days or 5 mg/day for 1–28 days; 28-day cycle… 
2004
2004
Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia.
To the Editor: Granulocyte colony-stimulating factor (G-CSF) given concurrently with chemotherapy was recently shown to improve… 
2001
2001
Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34+ cell dose
We have performed univariate and multivariate analysis to determine the factors that affect the kinetics of neutrophil and… 
1999
1999
A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer
Purpose: We administered chemotherapy consisting of a combination of 5-day continuous infusion of cisplatin (20 mg/m2 per day… 
1998
1998
Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.
PURPOSE To evaluate the impact of granulocyte colony-stimulating factor (G-CSF) priming on peripheral-blood cell counts during… 
Review
1998
Review
1998
Secondary or therapy-related MDS and AML and their chromosome aberrations: important to study but difficult to establish causality.
Correspondence: Jens Pedersen-Bjergaard, M.D., Ph.D., The Laboratory for Cancergenetics and Cytogenetics, Section 5702, The… 
1996
1996
Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
BACKGROUND Increased proliferation of endogenous bone marrow progenitor cells in response to the administration of hematopoietic… 
1996
1996
Use of G-CSF to Sustain Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Pilot Study.
BACKGROUND: Adjuvant chemotherapy for breast cancer is frequently accompanied by neutropenia requiring dose reduction or… 
1994
1994
Intensification of the CHOEP Regimen for High-Grade Non- Hodgkin’s Lymphoma by G-CSF: Feasibility of a 14-Day Regimen
Background: The efficacy of chemotherapy protocols for the treatment of high-grade non-Hodgkin’s lymphoma (NHL) has not improved… 
1992
1992
Interactions between recombinant human erythropoietin and serum factor(s) on murine megakaryocyte colony formation.
We investigated the interactions between human erythropoietin (hEpo) and serum factor(s) on murine megakaryocyte (MK) colony…